Beyond the Molecule: The New Competitive Battlefield in Oncology

For decades, the pharmaceutical industry operated under a relatively straightforward strategic assumption: discover the best molecule, prove superior efficacy, secure regulatory approval, scale commercialization, and dominate the market.

That model built some of the most valuable companies in healthcare history. In oncology especially, the molecule became the center of gravity.

Scientific innovation drove valuation, physician adoption, market access, and investor confidence. The companies that won were typically those with the strongest clinical data, deepest pipelines, and largest commercial footprints.

But oncology is entering a different era. The industry is shifting from a molecule-centered model to a systems-centered model and that transition may fundamentally redefine where competitive advantage comes from over the next decade.

The most successful oncology companies of the future may not simply be the companies with the best therapies but companies that best orchestrate the increasingly complex healthcare ecosystems surrounding those therapies. That distinction is critically important because oncology’s greatest challenges are no longer purely scientific.

Increasingly, they involve coordination gaps, operational hurdles, diagnostic fragmentation, reimbursement complexity, data integration barriers, and workflow inefficiencies. In other words, the next major oncology breakthrough may involve more than discovering better drugs. It may require redesigning how the entire oncology system functions around the patient.

Oncology is Evolving into a Systems Challenge

One of the least appreciated realities in oncology today is that scientific progress itself is generating enormous complexity. Precision medicine has transformed cancer care.

Molecular profiling, immunotherapies, chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies, antibody-drug conjugates, and circulating tumor DNA (ctDNA) testing are enabling increasingly personalized treatment strategies. But every layer of precision also introduces another layer of operational coordination.

A modern oncology patient journey may now involve genomic sequencing, biomarker testing, liquid biopsy analysis, specialty pharmacy coordination, prior authorization approval, infusion center scheduling, longitudinal disease monitoring, and ongoing molecular reassessment.

This is no longer a simple prescribing model. It is a multi-node healthcare coordination system and the truth is that the healthcare system is often poorly designed to manage this level of complexity efficiently.

Patients experience delays; biomarker testing rates remain inconsistent; data systems do not communicate effectively; referral pathways are fragmented; community oncology practices may lack infrastructure; payers create administrative friction; and physicians face cognitive overload from rapidly evolving treatment pathways.

As a result, many oncology launches underperform because the healthcare ecosystem cannot absorb innovation efficiently enough. Historically, pharma companies competed primarily on clinical differentiation. Increasingly, they may compete on ecosystem execution.

Oncology’s Biggest Competitive Risk Lies Outside the Drug

For years, oncology companies viewed competition through a scientific lens:

• Better efficacy
• Better progression-free survival
• Better overall survival
• Better biomarkers
• Better mechanisms of action

Those factors still matter deeply, but they may no longer be sufficient. The industry may be overestimating scientific differentiation while underestimating systemic friction.

This is one of the most counterintuitive strategic vulnerabilities facing oncology executives today. A highly effective therapy may still struggle commercially because:

• Eligible patients are not identified early enough.
• Molecular testing is inconsistent.
• Prior authorization delays create patient drop-off.
• Treatment pathways are operationally difficult.
• Community practices lack infrastructure.
• Patients cannot navigate the system effectively.

In many cases, the breakdown is not therapeutic failure but occurs within the surrounding ecosystem. That is a radically different way to think about oncology competition.

The future winner may not necessarily be the company with the single best molecule but the company that removes the greatest amount of friction from the oncology journey.

CAR T-Cell Therapy Changed the Rules of Competition

No area illustrates this shift more clearly than CAR T-cell therapy. Scientifically, CAR T represents one of the most remarkable breakthroughs in modern medicine.

But commercially and operationally, it also exposed something the industry was not fully prepared to acknowledge: Advanced oncology therapies increasingly function less like products and more like healthcare delivery systems.

CAR T-cell therapies require:

• Patient identification
• Cell extraction
• Individualized manufacturing
• Cryogenic logistics
• Specialized treatment centers
• ICU-level toxicity management
• Long-term monitoring

The therapy is inseparable from the infrastructure surrounding it. That fundamentally alters how competitive advantage is created.

Two therapies with similar efficacy may perform very differently based on:

• Manufacturing turnaround times
• Treatment center integration
• Operational reliability
• Reimbursement support
• Adverse event management
• Provider confidence

Operational excellence is increasingly functioning as clinical strategy. Historically, operations supported the molecule.

Now, operations are emerging as part of the molecule’s value proposition itself. That represents a major philosophical shift for the pharmaceutical industry.

Diagnostics May Rival the Sales Force in Strategic Importance

Another major transformation is occurring around diagnostics. Under the traditional pharma model, the physician served as the primary gatekeeper in pharma commercialization.

But in precision oncology, diagnostics increasingly determine therapy access before prescribing decisions even occur. Companion diagnostics, genomic profiling, and ctDNA testing are rapidly emerging as the new gatekeepers of oncology care.

This changes the commercial battlefield dramatically. In non-small cell lung cancer, for example, patients may undergo extensive molecular testing involving EGFR, ALK, ROS1, RET, MET, KRAS, HER2, BRAF, and other biomarkers before therapy selection occurs.

The company most deeply embedded in the diagnostic workflow may gain enormous strategic advantages long before a physician writes a prescription. This forces pharmaceutical executives to confront a larger strategic reality:

What if future oncology market share is determined less by sales force scale and more by diagnostic ecosystem influence? That possibility fundamentally reshapes commercialization strategy.

Counterintuitively, future oncology leaders may allocate proportionally less toward expanding sales representatives and substantially more toward:

• Diagnostic partnerships
• Workflow integration
• AI-enabled provider support
• Data infrastructure
• Patient navigation systems
• Real-world evidence platforms

The future competitive edge may belong to the company that simplifies complexity not merely the company that communicates clinical data most aggressively.

Roche May Already Be Positioned for This Future

One company that may already reflect elements of this future model is Roche. For years, Roche’s integration of pharmaceuticals and diagnostics appeared somewhat unique relative to many peers. But in the era of precision oncology, that structure increasingly appears strategically aligned with where the market is heading.

Roche participates not only in therapeutics, but also in:

• Biomarker testing
• Diagnostics
• Pathology workflows
• Disease monitoring
• Patient identification

That creates strategic advantages extending beyond the molecule itself.

Importantly, this does not necessarily mean every pharmaceutical company must vertically integrate diagnostics. But it does suggest that future oncology leaders may require much deeper ecosystem integration than traditional pharma models historically demanded.

AI Could Redistribute Competitive Power

Artificial intelligence may accelerate these dynamics even further.

Modern oncology generates enormous amounts of fragmented data:

• Genomics
• Imaging
• Pathology
• Biomarker analytics
• Outcomes data
• Longitudinal monitoring
• Trial matching information

No physician or pharmaceutical organization can process this efficiently at scale without computational support. AI therefore has the potential to function as the connective infrastructure layer of oncology. But there is also a deeper strategic implication that many companies may still underestimate.

Traditionally, pharmaceutical companies benefited from information asymmetry. They often possessed superior clinical and market knowledge relative to providers and health systems.

AI may gradually reduce that advantage. As clinical intelligence becomes increasingly democratized through AI-enabled systems, competitive advantage may shift away from information ownership and toward ecosystem execution.

That is subtle but potentially transformational. The future winner may not be the company that owns the most information but those that integrates information most effectively into clinical workflows.

Oncology Economics Are Entering a Critical Turning Point

Another issue the industry may still be underappreciating is cumulative oncology economics. The central constraint is no longer simply the price of individual therapies. The larger concern is the total cost of the oncology ecosystem.

Precision oncology increasingly involves:

• combination therapies
• companion diagnostics
• continuous biomarker testing
• advanced imaging
• cell therapies
• longitudinal monitoring
• AI infrastructure

Health systems are beginning to confront the reality that the cumulative economics of modern oncology may become difficult to sustain indefinitely. This could create major strategic consequences. Future payer pressure may focus less on individual drug pricing and more on total pathway economics.

Companies capable of demonstrating:

• Faster diagnosis
• Better care coordination
• Reduced hospitalizations
• Improved adherence
• Lower operational friction
• Better long-term outcomes

may gain substantial advantages in future reimbursement environments. This means value creation itself may increasingly shift from the product level to the ecosystem level.

Pharma’s Greatest Vulnerability May Be Organizational Fragmentation

Perhaps the industry’s greatest weakness today is internal fragmentation. Many pharmaceutical companies still operate through siloed structures:

• Commercial
• Medical affairs
• Diagnostics
• Market access
• Data analytics
• Manufacturing
• Digital health
• Patient support

But the oncology ecosystem no longer functions in silos. Precision oncology requires coordination across all of these functions simultaneously.

Yet many organizations remain optimized for the blockbuster era rather than the ecosystem era. This creates a dangerous mismatch between how oncology functions externally and how pharmaceutical companies operate internally.

Future leaders may require entirely new organizational models built around:

• Integrated patient pathways
• Cross-functional oncology platforms
• Real-world evidence loops
• AI-enabled coordination
• Data ecosystem management

The future oncology company may increasingly resemble a healthcare systems integrator as much as a pharmaceutical manufacturer.

The Future Oncology Winner May Look Very Different

The pharmaceutical industry has historically defined itself around products. But oncology may increasingly operate as an orchestration industry. The future winners may not simply invent breakthrough therapies. They may become the companies that best coordinate:

• Diagnostics
• AI systems
• Providers
• Data flows
• Manufacturing
• Reimbursement
• Patient navigation
• Long-term monitoring
• Real-world evidence generation

That is a much broader strategic role than pharma has traditionally occupied and it may represent one of the most important competitive shifts facing the industry over the next decade. Because ultimately, the future winner in oncology may not be the company with the single best molecule. It may be the company that best designs and orchestrates the entire oncology ecosystem surrounding the patient.

About the Author

Thani Jambulingam, PhD, is a professor in food, pharma and healthcare at Erivan K. Haub School of Business, Saint Joseph’s University, Philadelphia. He is a pharma and healthcare strategist and his work focuses on AI-enabled decision frameworks, emerging technologies, and commercial strategy. He can reached at tjambuli@sju.edu.